Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2022 Financial Results on March 1, 2023
February 09, 2023 07:30 ET
|
Organogenesis Holdings Inc.
CANTON, Mass., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization...
Organogenesis Holdings Inc. to Participate in the Cantor Fitzgerald Medical and Aesthetic Dermatology, Ophthalmology and Medtech Conference
December 05, 2022 07:30 ET
|
Organogenesis Holdings Inc.
CANTON, Mass., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of...
Organogenesis Holdings Inc. Reports Third Quarter 2022 Financial Results
November 09, 2022 16:05 ET
|
Organogenesis Holdings Inc.
CANTON, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of...
Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2022 Financial Results on November 9, 2022
September 26, 2022 09:12 ET
|
Organogenesis Holdings Inc.
CANTON, Mass., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization...
Organogenesis Holdings Inc. to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
September 07, 2022 07:30 ET
|
Organogenesis Holdings Inc.
CANTON, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization...
Organogenesis Receives FDA Clearance for Next Generation PuraPly Surgical Solution
August 15, 2022 07:00 ET
|
Organogenesis Holdings Inc.
CANTON, Mass., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Organogenesis, a leading regenerative medicine company, today announced it has received U.S. Food and Drug Administration (FDA) 510k Clearance for...
Organogenesis Holdings Inc. Reports Second Quarter 2022 Financial Results
August 09, 2022 16:05 ET
|
Organogenesis Holdings Inc.
CANTON, Mass., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of...
Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2022 Financial Results on August 9, 2022
June 30, 2022 07:30 ET
|
Organogenesis Holdings Inc.
CANTON, Mass., June 30, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of...
Organogenesis Holdings Inc. Reports First Quarter 2022 Financial Results
May 10, 2022 16:05 ET
|
Organogenesis Holdings Inc.
CANTON, Mass., May 10, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of...
Organogenesis Appoints Michele Korfin and Gilberto Quintero, Ph.D. to Board of Directors
May 05, 2022 16:05 ET
|
Organogenesis Holdings Inc.
CANTON, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of...